SCHEMBL1243634

SCHEMBL1243634

CC(C)(C)c1ccc(N=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A2 O15244 1/20 0.52
SLC22A1 O15245 1/20 0.52
SLC22A3 O75751 1/20 0.52
TSHR P16473 2/20 0.48
ALDH1A1 P00352 4/20 0.46
HSD17B10 Q99714 2/20 0.46
TP53 P04637 1/20 0.46
MAPK1 P28482 1/20 0.46
HIF1A Q16665 1/20 0.46
LMNA P02545 1/20 0.46
TYR P14679 1/20 0.46
CA1 P00915 4/20 0.46
CA2 P00918 4/20 0.46
HDAC1 Q13547 1/20 0.41
SRD5A2 P31213 1/20 0.40
GRIN2D O15399 1/20 0.39
GRIN3B O60391 1/20 0.39
GRIN1 Q05586 1/20 0.39
GRIN2A Q12879 1/20 0.39
GRIN2B Q13224 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14847408 0.84 HSD17B10 (0.46) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL24299172 0.84 ALDH1A1 (0.46) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL27252029 0.83 ALDH1A1 (0.44) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL27251896 0.78 TSHR (0.48) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL25564920 0.78 SLC22A2 (0.56) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL28652450 0.78 SLC22A2 (0.56) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL742186 0.78 SLC22A2 (0.56) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL13632763 0.78 SLC22A2 (0.56) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL27252024 0.77 ALDH1A1 (0.39) SLC22A2SLC22A1SLC22A3TSHRALDH1A1
SCHEMBL22423582 0.77 ESR1 (0.54) TSHRALDH1A1HSD17B10TP53MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260000640-A1 COMPOSITIONS AND METHODS FOR SKIN CARE ANTIPODEAN PHARMACEUTICALS INC (NZ) 2026-01-01 US claimed
US-20190008825-A1 COMPOSITIONS AND METHODS FOR SKIN CARE ANTIPODEAN PHARMACEUTICALS INC (NZ) 2019-01-10 US claimed
US-20170340603-A1 COMPOSITIONS AND METHODS FOR SKIN CARE ANTIPODEAN PHARMACEUTICALS INC (NZ) 2017-11-30 US claimed
US-20170246195-A1 MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS ANTIPODEAN PHARMACEUTICALS INC (NZ) 2017-08-31 US claimed
US-20110288055-A1 MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS TAYLOR KENNETH MARTIN (NZ) 2011-11-24 US claimed
US-7888335-B2 Antioxidant: methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives; Parkinson's, Alzheimer's disease, Huntington's Chorea and Friedreich's Ataxia ANTIPODEAN PHARMACEUTICALS, INC. (US) 2011-02-15 US claimed
US-20090258841-A1 COMPOSITIONS AND METHODS FOR SKIN CARE ANTIPODEAN PHARMACEUTICALS, INC. (NZ) 2009-10-15 US claimed
US-20080161267-A1 Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants ANTIPODEAN PHARMACEUTICALS, INC. (US) 2008-07-03 US claimed
WO-2008062210-A2 FREE RADICAL TRAPPING THE UNIVERSITY OF SALFORD (GB) 2008-05-29 WO claimed
US-20070225255-A1 Use of Mitochondrially Targeted Antioxidant in the Treatment of Liver Diseases and Epithelial Cancers ORIDIS BIOMED FORSCHUNGS-UND ENTWICKLUNGS GMBH (AT) 2007-09-27 US claimed
EP-1765413-A2 MITOCHONDRIALLY TARGETED ANTIOXIDANTS IN THE TREATMENT OF LIVER DISEASES AND EPITHELIAL CANCERS Oridis Biomed Forschungs- und Entwicklungs GmbH (AT) 2007-03-28 EP claimed
JP-2007503387-A 2007-02-22 JP claimed
US-20060229278-A1 Mitoquinone derivatives used as mitochondrially targeted antioxidants ANTIPODEAN PHARMACEUTICALS, INC. (US) 2006-10-12 US claimed
EP-1664069-A1 MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS Antipodean Pharmaceuticals, Inc. (US) 2006-06-07 EP claimed
WO-2006005759-A2 MITOCHONDRIALLY TARGETED ANTIOXIDANTS IN THE TREATMENT OF LIVER DISEASES AND EPITHELIAL CANCERS ORIDIS BIOMED FORSCHUNGS- UND ENTWICKLUNGS GMBH (AT) 2006-01-19 WO claimed
EP-1047701-B1 MITOCHONDRIALLY TARGETED ANTIOXIDANTS ANTIPODEAN BIOTECHNOLOGY LTD (NZ) 2005-05-25 EP claimed
WO-2005019232-A1 MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS ANTIPODEAN PHARMACEUTICALS, INC. (US) 2005-03-03 WO claimed
JP-6239737-A None JP disclosed
WO-1999026582-A2 MITOCHONDRIALLY TARGETED COMPOUNDS UNIVERSITY OF OTAGO (NZ) 1999-06-03 WO disclosed
JP-H06239737-A BRAIN METABOLISM PROMOTING AND MEMORY IMPROVING AGENT YUNIE:KK 1994-08-30 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060229278-A1 Mitoquinone derivatives used as mitochondrially targeted antioxidants COQ8A, MFN2, SQOR SLC22A2 717/4885SLC22A1 772/4885SLC22A3 660/4885
US-20080161267-A1 Mitoquinone Derivatives Used as Mitochondrially Targeted Antioxidants PRDX5, MT-ND2, TXN2 SLC22A2 932/4885SLC22A1 994/4885SLC22A3 894/4885
US-20170246195-A1 MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS PRDX5, TXN2, MT-ND2 SLC22A2 1015/4885SLC22A1 1055/4885SLC22A3 945/4885
US-20260000640-A1 COMPOSITIONS AND METHODS FOR SKIN CARE TXN2, NDUFA2, NDUFA9 SLC22A2 255/4885SLC22A1 262/4885SLC22A3 244/4885
US-20070225255-A1 Use of Mitochondrially Targeted Antioxidant in the Treatment of Liver Diseases and Epithelial Cancers GLS2, PRDX5, GSR SLC22A2 1080/4885SLC22A1 923/4885SLC22A3 852/4885
US-20090258841-A1 COMPOSITIONS AND METHODS FOR SKIN CARE TFAM, HSPA9, MT-CO3 SLC22A2 316/4885SLC22A1 287/4885SLC22A3 242/4885
US-20110288055-A1 MITOQUINONE DERIVATIVES USED AS MITOCHONDRIALLY TARGETED ANTIOXIDANTS PRDX5, MT-ND2, TXN2 SLC22A2 932/4885SLC22A1 994/4885SLC22A3 894/4885
US-20190008825-A1 COMPOSITIONS AND METHODS FOR SKIN CARE TFAM, HSPA9, MT-CO3 SLC22A2 316/4885SLC22A1 287/4885SLC22A3 242/4885
US-20170340603-A1 COMPOSITIONS AND METHODS FOR SKIN CARE TFAM, HSPA9, MT-CO3 SLC22A2 316/4885SLC22A1 287/4885SLC22A3 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.